DERM
Journey Medical Corp.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$5.17
+4.13%Year over year
Reported trailing growth
- Revenue
- +20.9%
- EBITDA
- +257.5%
- EBIT
- +56.2%
- EPS
- +42.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +63.3%
- EBITDA
- +1023.7%
- EPS
- +248.3%
Three-year CAGR
- Revenue
- -5.7%
- EBITDA
- +60.4%
- EBIT
- +40.3%
- Net income
- +22.1%
- EPS
- +34.7%
- Free cash flow
- +48.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026